Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Study Examines Mechanism For Gene Alterations In Brain Tumors
In a related article appearing in the July 15 issue of JAMA, researchers have identified the mechanism linked to the alteration of certain genes cited by Bredel et al in the previous study.
generic viagra online
Most Complete Picture Of North American Industrial Pollution Presented In Latest Trinational Report
Ninety percent of the 5.5 billion kilograms of toxic pollutant releases and transfers reported in North America in 2005 can be traced to just 30 substances from 15 industrial sectors across the United States, Canada and Mexico, according to the latest tri-national pollution report from the Commission for Environmental Cooperation (CEC).
News of the day
Obama Announces Appeals Court Judge Sotomayor As Supreme Court Nominee
President Obama this morning announced Judge Sonia Sotomayor of the Second Circuit Court of Appeals as his nominee to replace retiring Supreme Court Justice David Souter, the New York Times" "The Caucus" reports. Sotomayor, if confirmed, would be the first Hispanic to serve on the court and, with Justice Ruth Bader Ginsburg, bring the number of female justices currently on the court to two. White House officials said the president made his decision over the Memorial Day weekend after narrowing his list of candidates to four. s close to the selection process said the other candidates included Federal Appeals Judge Diane Wood, Homeland Security Secretary Janet Napolitano and Solicitor General Elena Kagan (Zeleny, "The Caucus," New York Times, 5/26). According to the Washington Post, Obama has set a deadline of having Sotomayor confirmed before the Senate"s five-week recess that begins Aug. 7 (Shear et al., Washington Post, 5/26). Sotomayor, a graduate of Princeton University and Yale Law School, joined the federal district court in 1992 after being nominated by former President George H.W. Bush. Former President Clinton nominated her to the appeals court in 1997, and she was confirmed in 1998 (Baker/Zeleny, New York Times, 5/26). The Post reports that many analysts considered Sotomayor a likely pick to replace Souter, who announced his retirement earlier this month (Washington Post, 5/26). According to the Times, Sotomayor"s past statements that her ethnicity and gender are important factors in serving as a judge "could generate debate" during the nomination process. In a 2002 lecture, Sotomayor said, "I would hope that a wise Latina woman with the richness of her experiences would more often than not reach a better conclusion than a white male who hasn"t lived that life" (New York Times, 5/26). Both liberal and conservative advocates were quick to release statements on the selection after the announcement this morning. Doug Kendall, president of the liberal Constitution Accountability Center, said, "We already know that she is a brilliant lawyer who is committed to ruling based on the Constitution and the law, not on her own personal political views." Wendy Long, counsel to the conservative Judicial Confirmation Network, said in an e-mail to reporters that Sotomayor "is a liberal judicial activist of the first order who thinks her own personal political agenda is more important than the law as written. She thinks that judges should dictate policy, and that one"s sex, race and ethnicity ought to affect the decisions one renders from the bench" (Washington Post, 5/26). According to Politico, of the nominees Obama was considering, Sotomayor was the one that Republicans indicated "they would complain most loudly about." However, the Democratic control of the Senate makes it unlikely that Republicans could block her confirmation, Politico reports (Allen/Martin, Politico, 5/26). Over the weekend, Senate Minority Whip Jon Kyl (R-Ariz.), a member of the Senate Judiciary Committee, said that senators from both parties "reserve the right to not only oppose a nomination, but also prevent the vote on a nomination" (Wilson, The Hill, 5/25). Kyl also said that although the GOP likely does not have enough votes for a filibuster, he would attempt to delay the nomination if Obama chose someone outside what he considers the mainstream. He said, "We will distinguish between a liberal judge on one side and one who doesn"t decide cases on the merits but, rather, on the basis of his or her preconceived ideas" (Washington Times, 5/25). Obama Discusses Nomination in C-SPAN InterviewIn an interview on Friday with C-SPAN, Obama said he would like to choose a Supreme Court justice who has "a little bit of a common touch" and a "practical sense of how the world works," the Post reports. Obama added that he "continue[s] to believe" that "empathy" is an important quality in a justice, despite Republican criticism that his emphasis on the quality means that he seeks a judge with an "activist" agenda, the Post reports
Endocrinology

Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression And Cell Type Specificity

Bionovo, Inc. (Nasdaq: BNVI) announced that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates will be published in Public Library of Science One. "In this study we show that plant-derived ERb compounds are as selective as synthetic compounds, but regulate different genes. Specifically, we have discovered that these compounds do not promote breast or endometrial cancer in animal models, unlike many estrogen therapies. This suggests that these plant-derived ERb-selective compounds could lead to safer, more attractive alternative therapies for menopausal symptoms," said Dr. Dale Leitman, the Principal Investigator of the study. The publication describes the analyses of three distinct classes of ERb selective drugs. The study determines the relative ER selectivity and pattern of gene expression of the three classes of ERb selective compounds compared to the natural hormone estradiol, which non-selectively regulates both ERa and ERb . The most significant finding in the study was that the ERb-selective compounds regulate a number of genes differently than estradiol, a hormone therapy commonly used to treat women"s health issues. This discovery indicates that ERb agonists might be safer than current estrogens used in hormone therapy. The study also demonstrates the cell type selectivity of Menerba (MF101) and Liquiritigenin, two of Bionovo"s ERb selective drugs, in different cell types. These compelling findings will serve as a strong impetus for Bionovo, Inc. to continue investigating the unique abilities of their drugs to safely and effectively treat menopausal symptoms. "It is essential that new drug candidates demonstrate drug selectivity and tissue specificity in order to minimize adverse effects, particularly when the drug is being developed for the treatment of common, recurring symptoms associated with menopause, such as hot flashes. This is particularly important when developing drugs that mediate their effects through estrogen receptors, which are responsible for many functions in the body and are present in a range of different tissues. Bionovo stands alone in its dedication to identifying novel pathways in estrogen receptor signaling as drug targets for the treatment of women"s conditions," said Isaac Cohen, Chairman and CEO of Bionovo, Inc. "We have been endeavoring to develop more selective drugs in women"s health, and Dr. Leitman"s study highlights the solid scientific underpinnings of our ER beta selective drugs and underlines the deep biological understanding we have of the mechanisms through which they work." Bionovo, Inc. Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women"s health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical s which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". Forward Looking Statements This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Bionovo, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009